Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Blackman CF et al. | 1993 | intact cell/cell culture, PC-12 cells (pheochromocytoma cell line from rat adrenal gland) | electric field, magnetic field, 50/60 Hz | 0 nT–10.2 µT |
McFarlane EH et al. | 2000 | intact cell/cell culture, PC-12 cells (pheochromocytoma cell line from rat adrenal gland) | magnetic field, 50/60 Hz | 4.35–15.8 µT |
Blackman CF et al. | 1993 | intact cell/cell culture, PC-12D cells (subline of the PC-12 cell line, derived from pheochromocytoma cells from the rat adrenal medulla) | magnetic field, 50/60 Hz | 0.4–40 µT |
Santoro N et al. | 1997 | intact cell/cell culture, Raji cells (human Burkitt lymphoma B lymphocyte cell line) | magnetic field, 50/60 Hz | 2 mT |
Lisi A et al. | 2000 | intact cell/cell culture, Raji cells (human Burkitt lymphoma B lymphocyte cell line) | magnetic field, 50/60 Hz | 1 mT |
Girasole M et al. | 2001 | intact cell/cell culture, Raji cells (human Burkitt lymphoma B lymphocyte cell line) | magnetic field, 50/60 Hz | 2 mT |
Sulpizio M et al. | 2011 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz | 1 mT |
Hasanzadeh H et al. | 2014 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz | 2 mT |
Rezaie-Tavirani M et al. | 2017 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz | 0.5–1 mT |
Aparicio-Bautista DI et al. | 2022 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz, low frequency | - |
Calabrò E et al. | 2020 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | 50/60 Hz, magnetic field | - |
Schmidt-Rohlfing B et al. | 2008 | intact cell/cell culture, chondrocytes (from human articular cartilage of osteoarthritic knee joints) | magnetic field, low frequency, signals/pulses, 50/60 Hz, electrotherapy | 2 mT |
Verdugo-Diaz L et al. | 2002 | intact cell/cell culture, chromaffin cells (from neonatal rats) | magnetic field, 50/60 Hz | 700 µT |
Drucker-Colin R et al. | 1994 | intact cell/cell culture, chromaffin cells (from postnatal Wistar rat adrenal medulla) | magnetic field, 50/60 Hz, co-exposure | 700 µT |
Zhang L et al. | 1997 | intact cell/cell culture, chromaffin cells (from rat adrenal medulla) | magnetic field, 50/60 Hz | 1 mT |
Anaya M et al. | 2021 | intact cell/cell culture, fungal strains (<i>Aspergillus niger</i> Tiegh., <i>Penicillium citrinum</i> Thom., <i>Cladosporium cladosporioides</i> Fresen.) | 50/60 Hz, magnetic field | 1–5 mT |
Łach K et al. | 2021 | intact cell/cell culture, human adipose tissue mesenchymal stem cells (AT-MSCs) | 50/60 Hz, magnetic field | - |
Sendera A et al. | 2024 | intact cell/cell culture, human adipose-derived mesenchymal stem cells | magnetic field, 50/60 Hz, low frequency | - |
Wu X et al. | 2018 | intact cell/cell culture, human amniotic epithelium cells (FL), rat pheochromocytoma cells (PC12) | magnetic field, 50/60 Hz | 0.4 mT |
Nafziger J et al. | 1997 | intact cell/cell culture, human bone marrow cells | magnetic field, 50/60 Hz | 10 µT–1 mT |
Cho H et al. | 2012 | intact cell/cell culture, human bone marrow-derived mesenchymal stem cells (hBM-MSCs) | magnetic field, low frequency, 50/60 Hz | 1 mT |
Naghibzadeh M et al. | 2020 | intact cell/cell culture, human dermal fibroblasts | magnetic field, 50/60 Hz | 1–5 mT |
Bai WF et al. | 2012 | intact cell/cell culture, human epidermal stem cells of the foreskin | magnetic field, 50/60 Hz | 5 mT |
Milani M et al. | 2001 | intact cell/cell culture, human lymphocytes | magnetic field, 50/60 Hz | 50 µT |
Yan J et al. | 2010 | intact cell/cell culture, human mesenchymal stem cells | magnetic field, low frequency, 50/60 Hz | 20 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.